Tradestie Institutional Equity Comparison Engine
FGEN vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Overall Edge
AVDL Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FGEN trades at 61.4x Forward P/E with -499.1% operating margin (+774.8% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, FGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
AVDL
FGEN 61.4x vs AVDL 28.8x Fwd P/E
Growth & Margin Winner
AVDL
Op Margin -499.1% vs 2.5% ยท YoY +774.8% vs +54.9%
Momentum & Technical Winner
AVDL
1Y -28.8% vs +138.1% ยท 52W Pos 44% vs 89%
Options & Structure Winner
AVDL
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
FGEN
NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap
$36.5M
1M Return
+16.57%
1Y Return
-28.84%
Forward P/E
61.4x
Unified AI Score
61.2 / 100
BUY
Tech 60.0
Fund 56.0
Flow 50.0
Mom 60.0
AVDL
NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap
$2.1B
1M Return
+0.65%
1Y Return
+138.06%
Forward P/E
28.8x
Unified AI Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FGEN -28.84%
AVDL +138.06%
Spread: +158.57 pp (AVDL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
FGEN TTM Op. Margin: -499.1%
AVDL TTM Op. Margin: 2.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs AVDL. Trailing 12-month operating profitability (FGEN -499.1% vs AVDL 2.5%) and valuation multiples (FGEN 61.4x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FGEN | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $36.5M | $2.1B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | 61.4x | 16.8x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 61.4x | 28.8x | Lower Multiple | AVDL |
| Revenue Growth (YoY) Growth | +774.8% | +54.9% | Higher Growth | FGEN |
| Operating Margin (TTM) Profitability | -499.1% | 2.5% | Higher Margin | AVDL |
| Net Profit Margin Profitability | 2598.9% | -0.1% | Higher Margin | FGEN |
| Return on Equity (ROE) Capital Efficiency | -1015.8% | -0.3% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 44% ($0โ$22) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | -20.79ฮฒ ยท 102% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 61.2 / 100 (BUY) | 62.9 / 100 (BUY) | Higher Composite | AVDL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FGEN vs AVDL Buy Guide
FGEN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
AVDL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FGEN nor AVDL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.